- Home
- NVRI vs ORKA Comparison
NVRI vs ORKA Comparison
Compare NVRI & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVRI | ORKA |
|---|---|---|
| Founded | 1853 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | NVRI | ORKA |
|---|---|---|
| Price | $18.83 | $44.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $57.25 |
| AVG Volume (30 Days) | ★ 1.3M | 562.0K |
| Earning Date | 04-30-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,240,358,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.72 | $5.49 |
| 52 Week High | $19.48 | $47.25 |
Technical Indicators
Market Signals| Indicator | NVRI | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 58.12 | 67.10 |
| Support Level | $18.65 | $26.02 |
| Resistance Level | $19.45 | N/A |
| Average True Range (ATR) | 0.40 | 3.24 |
| MACD | 0.11 | 0.71 |
| Stochastic Oscillator | 89.42 | 84.37 |
Price Performance
Historical ComparisonAbout NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.